February 22, 2010
Pulmonx Raises $32 Million for Launch of Emphysema Products
February 16, 2010
Moksha8’s sales of US$ 140 million here in 9 months with Roche; operations to expand; up to 20% per Mexican partner
January 12, 2010
moksha8 and BioCryst Gain Approval for the Importation and Use of Peramivir in Mexico for the Treatment of H1N1 Influenza
November 18, 2009
Daniel K. Turner III Named to AlwaysOn Top Venture Capitalists in Inaugural VC 100 List
November 16, 2009
NeurogesX Receives FDA Approval of QutenzaTM (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
November 12, 2009
Montreux Equity Partners leads a $25 million financing in Moksha8, a specialty pharmaceutical company focused on Latin America
September 30, 2009
Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
August 3, 2009
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo® in the United States
July 20, 2009
Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments
June 22, 2009
NeurogesX and Astellas Enter Commercialization Agreement for Qutenza™
June 10, 2009
Bayhill Therapeutics Enters Exclusive, Worldwide Collaboration with Genentech for BHT-3021 in Type 1 Diabetes
May 11, 2009
SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.
December 2, 2008
MAKO Surgical Corp. Receives FDA Clearance to Market Both its Version 2.0 Tactile Guidance System ™ and its Bicompartmental Knee Resurfacing Implant System
October 29, 2008
MAKO Surgical Corp. Announces up to $60 Million Private Placement Financing from Three Leading Health Care Investment Firms
October 1, 2008
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo® for Treatment of Middle-of-the-Night Awakenings
June 19, 2008
Cerexa/Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
May 12, 2008
Novalar Receives FDA Approval for OraVerse™
January 3, 2008
Montreux Equity Partners Closes $250 Million MEP IV Life Sciences Fund
December 26, 2007
NeurogesX, Inc. Announces $25 Million Private Placement
November 7, 2007
ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
October 1, 2007
SkinMedica: MIP Awards Finalist
September 24, 2007
Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
September 4, 2007
ARYx Seeking $86M In IPO For Work On Large-Market Products
September 4, 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical
August 30, 2007
ARYx Therapeutics Files Registration Statement for Initial Public Offering
August 10, 2007
KFx Medical Corporation Closes $10 million Series B Financing
August 1, 2007
Tobira Therapeutics Inc. Completes $31 Million Series A Financing and Names Management Team
July 25, 2007
Merck & Co., Inc. to Acquire NovaCardia, Inc., to Boost Clinical Pipeline of Cardiovascular Drug Candidates
July 24, 2007
OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial ofv EMPATIC(TM) to Treat Obesity
May 15, 2007
Asthmatx Announces $50 millon Investment by Olympus Medical Systems Corp.
May 2, 2007
NeurogesX, Inc. Prices Initial Public Offering
April 26, 2007
OREXIGEN Therapeutics Announces Pricing of its Initial Public Offering
March 29, 2007
NovaCardia Files Registration Statement for Proposed Initial Public Offering
March 29, 2007
New England Journal of Medicine: Report shows Improved Asthma Control One Year following a New Outpatient Procedure for Asthma.
March 6, 2007
TransOral Pharmaceuticals Raises $40 Million in Series D Financing. Proceeds Will Be Used to Complete Intermezzo™ Phase 3 Clinical Trials and File NDA.
February 21, 2007
ARYx Therapeutics Appoints New Chief Development Officer
February 13, 2007
Somaxon Provides Update on SILENOR™ Preclinical Program
February 7, 2007
NeurogesX, Inc. Files Registration Statement for Initial Public Offering of Common Stock
February 6, 2007
NovaCardia Appoints Joseph L. Turner to its Board of Directors
January 11, 2007
Forest Laboratories Completes Acquisition of Cerexa
January 4, 2007
NovaCardia Appoints John E. Crawford as Chief Financial Officer
December 19, 2006
OREXIGEN™ Therapeutics files registration statement for proposed initial public offering
December 18, 2006
Somaxon’s SILENOR™ Demonstrates Positive Results in Long-Term Phase 3 Clinical Trial in Elderly Patients with Insomnia
December 14, 2006
Cerexa to be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
November 22, 2006
OREXIGEN™ Therapeutics completes $30 million Series C financing
November 15, 2006
NOVALAR’s Positive Phase 2 Pediatric Study Results Support Recent Pivotal Data in Adolescents and Adults
November 14, 2006
NovaCardia Presents Phase II Data for KW-3902 at American Heart Association’s 79th Annual Scientific Sessions
November 9, 2006
OREXIGEN™ Therapeutics announces issuance of broad patents covering composition of its lead anti-obesity compounds
November 7, 2006
SkinMedica and Galderma to Co-promote Desonate™ New Innovative Formula for Atopic Dermatitis
October 31, 2006
Avantis Medical Systems, Inc. Closes Series B Financing; $12 Million to Fund Development and Commercialization of Third Eye Retroscope(TM) Device for Improving Detection of Colon Cancer
October 23, 2006
Somaxon Pharmaceuticals’ SILENOR™ Demonstrates Positive Results in a Phase 3 Transient Insomnia Clinical Trial
October 23, 2006
SkinMedica® Announces FDA Approval of Desonate (TM) (desonide) Gel 0.05% with Patented Hydrogel Technology for Treatment of Atopic Dermatitis
October 22, 2006
OREXIGEN™ Therapeutics reports positive Phase II results for EXCALIA™ combination-therapy to treat obesity
October 18, 2006
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
October 4, 2006
OREXIGEN™ Therapeutics expands senior management team as lead products advance through late-stage clinical trials
October 3, 2006
NOVALAR announces positive Phase 3 results for novel dental anesthesia reversal agent
September 26, 2006
OREXIGEN™ Therapeutics reports positive 24-week results for CONTRAVE™ Phase IIb* obesity treatment study
September 26, 2006
OREXIGEN™ Therapeutics reports positive 24-week results for CONTRAVE™ Phase III obesity treatment study
September 25, 2006
NovaCardia Raises $48 Million in Series B
August 21, 2006
Verus Pharmaceuticals Announces Agreement with UCB for Commercialization of Twinject® in Europe
August 10, 2006
KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
August 2, 2006
Cerexa Reports Positive Top-Line Results for Phase 2 Clinical Trial of Ceftaroline
July 24, 2006
UPDATE 1-Asthmatx files with U.S. SEC for $75 mln IPO
July 11, 2006
Procter & Gamble Pharmaceuticals and Aryx Therapeutics form Alliance for an Investigational Treatment for Gastrointestinal Disorders
June 27, 2006
Avera Pharmaceuticals Completes Successful Phase 2 Study of Gantacurium Chloride for Endotracheal Intubation
June 10, 2006
Orexigen™ Therapeutics Reports Positive Phase II Results for Contrave™ Combination-Therapy to Treat Obesity
May 10, 2006
Somaxon Pharmaceuticals Reports 2006 First Quarter
April 30, 2006
Scientists demonstrate investigational MS drug down regulates the underlying cause believed responsible for multiple sclerosis at the 16th Meeting of the European Neurological Society
April 11, 2006
SkinMedica Closes $11 Million Round of Financing
April 5, 2006
Cerexa Announces Completion of Enrollment in Ceftaroline Phase 2 Trial
March 16, 2006
NOVALAR™ Initiates Pivotal Phase 3 Studies for Novel Dental Anesthesia Reversal Agent
March 7, 2006
Verus Pharmaceuticals Announces Study Results Supporting the Potential Need for Two Doses of Epinephrine to Treat Anaphylaxis
February 21, 2006
SkinMedica® Reports Positive Results From Desonate™ Phase III Trials; First Topical Steroid Using Patented HydroGel™ Technology
February 7, 2006
ARYx Therapeutics Completes Series Financing
January 3, 2006
NovaCardia Announces Positive Phase 2 Results For KW-3902
December 15, 2005
Somaxon Pharmaceuticals, Inc. announces initial public offering
September 22, 2005
Verus Pharmaceuticals Announces Canadian Launch of Twinject for Anaphylaxis
August 23, 2005
Cerexa, Inc. Announces Corporate Launch and $50 Million Initial Financing
August 17, 2005
NovoStent Completes Second Close Raising a Total of $12.75 Million in New Financing
August 16, 2005
Verus Pharmaceuticals Announces U.S. Launch of Twinject for Anaphylaxis
July 27, 2005
Verus Pharmaceuticals Announces Agreement with Paladin Labs for Commercialization of Twinject in Canada
July 23, 2005
A Californian Coming of Age
June 9, 2005
Somaxon Pharmaceuticals, Inc. Initiates Phase III Clinical Trials of SILENOR™ in Patients with Insomnia
June 9, 2005
Verus Pharmaceuticals Announces $98 Million Financing Largest Ever Series A Financing in San Diego
June 6, 2005
Somaxon Pharmaceuticals, Inc. Announces $65 Million Financing
April 18, 2005
Johnson & Johnson Announces Agreement to Acquire Peninsula Pharmaceuticals, Inc.
April 13, 2005
Montreux Equity Partners Names Manish Chapekar General Partner
March 9, 2005
Questcor Announces Financial Results for the Quarter and Year Ended December 31, 2004
September 14, 2004
Peninsula Pharmaceuticals Names Dennis Podlesak Chief Executive Officer and President
August 4, 2004
Avera Pharmaceuticals Raises $48 Million in Series C Venture Financing
July 14, 2004
SkinMedica Raises Additional $40 Million Financing; Company Closes Acquisition of VANIQA Pharmaceutical Product
June 28, 2004
SkinMedica to Acquire VANIQA to Expand Prescription Dermatology Product Line
June 15, 2004
Somaxon Pharmaceuticals, Inc. Closes $23 Million Financing
June 10, 2004
Peninsula Pharmaceuticals, Inc. Begins Phase III Clinical Trial of Doripenem for the Treatment of Hospital-Acquired Pneumonia
June 4, 2004
Howard Palefsky is Venture Reporter's Venture Capitalist of the Week
June 1, 2004
ARYx Therapeutics Completes Series D Financing
April 7, 2004
Peninsula Pharmaceuticals, Inc. Announces Results of Preclinical Study Comparing Nebulized Doripenem vs. Tobramycin in a Murine Model of Acute, Severe Pseudomonas aeruginosa Pneumonia
February 24, 2004
NeurogesX Receives $35 Million in Series C Round
January 13, 2004
Montreux Equity Partners Announces Closing of Life Sciences Focused MEP III Fund
July 24, 2003
TransOral Pharmaceuticals Completes Initial Institutional Private Equity Financing
April 24, 2003
Boston Scientific Garners FDA Okay for GERD Implant Device
January 16, 2003
Questcor Completes $10 Million Private Placement
January 13, 2003
Questcor to Raise $10 Million in a Private Placement
June 13, 2002
Boston Scientific Announces Completion of Enteric Medical Technologies, Inc. Acquisition
May 30, 2002
Boston Scientific Announces Definitive Agreement To Acquire Enteric Medical Technologies, Inc.
| 
